EP1713466B1 - Antiparasitic composition containing an organic amine salt of closantel - Google Patents

Antiparasitic composition containing an organic amine salt of closantel Download PDF

Info

Publication number
EP1713466B1
EP1713466B1 EP05712747A EP05712747A EP1713466B1 EP 1713466 B1 EP1713466 B1 EP 1713466B1 EP 05712747 A EP05712747 A EP 05712747A EP 05712747 A EP05712747 A EP 05712747A EP 1713466 B1 EP1713466 B1 EP 1713466B1
Authority
EP
European Patent Office
Prior art keywords
closantel
salt
moxidectin
use according
ethanol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP05712747A
Other languages
German (de)
French (fr)
Other versions
EP1713466A2 (en
Inventor
Robert Bruce Albright
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Priority to EP09003554A priority Critical patent/EP2065042A3/en
Publication of EP1713466A2 publication Critical patent/EP1713466A2/en
Application granted granted Critical
Publication of EP1713466B1 publication Critical patent/EP1713466B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/08—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
    • C07C255/44—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms at least one of the singly-bound nitrogen atoms being acylated

Definitions

  • Parasites such as helminths
  • helminths are found in many animals, particularly grazing animals, and are responsible for significant economic losses throughout the world.
  • helminths most frequently encountered in grazing animals such as cattle, horses, goats and sheep are trematodes, i . e ., flukes, for instance, Fasciola hepatica, and nematodes such as Haemonchus contortus.
  • a valuable tool for the treatment of homeothermic animals suffering from such parasites is closantel (United States Patent 4,005,218 and Merck Index, 13 th Edition).
  • Closantel is known to demonstrate little or no capacity for transdermal penetration at present, so the most effective means of administering closantel involves parenteral or oral administration.
  • Closantel is sold as its sodium salt, under Flukiver® for subcutaneous administration and Seponver® as an oral drench.
  • Flukiver® for subcutaneous administration
  • Seponver® as an oral drench.
  • closantel compositions which exhibit improved transdermal penetration properties, as well as increased bioavailability. It is apparent that, not withstanding high safety margins, a lower but effective dosage is always preferred.
  • US-A-4 005 218 discloses salicylanilide derivatives, including closantel and amine addition salts thereof, which are parasiticides with activity against, inter alia, Fasciola hepatica or Haemonchus contortus.
  • amine salts are the piperidine, piperazine, triethylamine, N-methylglucamine, methylamine, ⁇ -methylbenzylamine and ethanolamine salts.
  • the compounds can be administered orally, parenterally or by external application by direct contact onto the skin.
  • the improved antiparasitic compositions are to be administered to a homeothermic animal by transdermal application, either alone, or in combination, with other antiparasitic compounds, as specified in claim 1.
  • the present invention provides the use of an antiparasitic composition having improved blood levels of closantel which comprises an antiparasitically effective amount of an alkanolamine salt of closantel, optionally an antiparasitically effective amount of a macrocyclic lactone, and a pharmacologically acceptable carrier, as specified in claim 1, in the manufacture of a medicament for the enhanced prevention, amelioration or control of a parasitic infection in a homeothermic animal by transdermal administration.
  • closantel is known to be effective as a flukicide, its topical application has been limited due to its low capacity for transdermal penetration.
  • an antiparasitic composition having an alkanolamine salt of closantel as an active component, significantly increases the bioavailability of closantel. While not wishing to be bound by a particular theory, it is believed that in its alkanolamine salt form, for example, as the ethanolamine salt, closantel is absorbed by passive diffusion in the liver. This achieves higher liver levels and, consequently, higher blood levels.
  • an antiparasitic composition for use in the invention containing an alkanolamine salt of closantel demonstrates improved transdermal penetration properties, thus allowing for administration in the form of a pour-on composition.
  • Pour-on compositions are particularly suitable for treating parasites in grazing animals such as cattle, goats or sheep.
  • the composition for use in the invention may also be suitable for administration by intramuscular or subcutaneous injection at a diversity of sites on an animal.
  • a further advantage of the use of the organic amine salt is that such can be more easily formulated with other anthelmintic agents, particularly those of the macrocyclic lactone type, which results in compositions that can be utilized to treat both nematodes and flukes (trematodes) in a single application.
  • the present invention provides the use of an improved antiparasitic composition which comprises an antiparasitically effective amount of an alkanolamine salt of closantel, and a pharmacologically acceptable carrier, and optionally a macrocyclic lactone, according to claim 1, for the manufacture of a medicament for the prevention, amelioration or control of a parasitic infection in a homeothermic animal by transdermal administration.
  • Alkanolamine salts of closantel suitable for use in the invention include alkanolamine salts having 2-10 carbon atoms, and most preferred are the ethanolamine salts, i.e., closantel monoethanolamine or diethanolamine salts. Typically, such salts are prepared by contacting closantel with a solution of the alkanolamine.
  • Organic amine salts are generally described, for instance, in United States Patent 4,005,218 .
  • Macrocyclic lactones for use in the invention are milbemycins and avermectins selected from moxidectin, abamectin, ivermectin, eprinomectin and doramectin, and preferably moxidectin. These compounds, and their anthelmintic activity, are described more particularly in U.S. Patent 4,916,154 (moxidectin), U.S. Patent 4,310,519 (abamectin), U.S. Patent 4,199,569 (ivermectin), U.S. Patent 4,427,663 (eprinomectin).
  • the pharmacologically acceptable carrier for use in the compositions of the present invention can be selected from typical solvents and excipients utilized for veterinary formulations.
  • the alkanolamine salt of closantel is dissolved in the carrier, although suspensions in either liquid or gel formulations are also effective.
  • a macrocyclic lactone is included as an optional ingredient, it may be present either in solution or in suspension.
  • Alcohols suitable for use in the composition for use in the invention include ethanol, benzyl alcohol, isopropanol, butanol, or a mixture thereof, with ethanol, benzyl alcohol or a mixture thereof being preferred.
  • Glycol derivatives suitable for use in the invention include propylene glycol, diethylene glycol monoethyl ether (transcutol), ethylene glycol, butylene glycol, polyethylene glycol, and preferably are propylene glycol, diethylene glycol monoethyl ether or a mixture thereof.
  • Antiparasitically effective amounts may vary according to the mode of application, the degree of infection, the target parasite species, the host homeothermic animal. In general, amounts of 5% w/v to 60% w/v of an alkanolamine salt of closantel, and optionally 0.1% w/v to 5.0% w/v of a macrocyclic lactone, are suitable for use in the invention.
  • compositions for use in the invention may also include excipients such as surfactants, preferably oleic acid, thickening agents, salts, buffers, polyvinylpyrrolidone, or any conventional inert excipient commonly used in a pharmaceutical composition.
  • excipients such as surfactants, preferably oleic acid, thickening agents, salts, buffers, polyvinylpyrrolidone, or any conventional inert excipient commonly used in a pharmaceutical composition.
  • the amount of said excipients may range from 0.1% w/v to 20% w/v.
  • compositions for use in the invention may be prepared by admixing a glycol derivative with the alkanolamine salt of closantel and allowing said salt of closantel to solubilize to give a solution of the alkanolamine salt of closantel in the glycol derivative and treating this solution with an alcohol, which may optionally contain a macrocyclic lactone.
  • compositions for use in the invention provide increased blood levels of closantel which are associated with the enhanced protection of a homeothermic animal against infection or infestation of parasites, particularly helminths.
  • Homeothermic animals suitable for treatment of the invention include grazing animals such as cattle, goats, sheep, llamas, deer, bison, etc.
  • Effective amounts may vary according to the general health of the animal, the degree of infection of infestation, the parasite species, the age of the animal, the organs infected or infested. In general, amounts of said composition sufficient to provide 5 mg/kg to 100 mg/kg, preferably 25 mg/kg to 50 mg/kg of closantel per body weight of the animal, and, optionally, 0.1 mg/kg to 2.0 mg/kg, preferably 0.1 mg/kg to 1.0 mg/kg of moxidectin per body weight of the animal are suitable.
  • a stirred mixture of closantel in diethylene glycol monoethyl ether is treated with ethanolamine, and stirring is continued until solution is complete, thus forming the salt in situ.
  • To this solution is then added a solution of moxidectin in benzyl alcohol, followed by the addition of oleic acid and ethanol. Stirring is continued until the mixture is homogeneous.
  • a stirred mixture of sodium closantel in diethylene glycol monoethyl ether is treated with ethanol amine, and stirring is continued until solution is complete, thus forming the salt in situ.
  • To this solution is then added a solution of oleic acid and ethanol. Stirring is continued until the mixture is homogeneous.
  • a solution of the ethanolamine salt of closantel in propylene glycol is stirred until homogenous, thus forming the salt in situ.
  • a solution of polyvinylpyrrolidone in deionized water, ethanol and additional propylene glycol is stirred until homogeneous.
  • N-methylglucamine is added to a suspension of closantel in ethanol, benzyl alcohol, and propylene glycol. With stirring, the salt of closantel forms in situ, forming a solution. Moxidectin is then added, and stirred until solution is obtained. The formulation is then brought to volume with propylene glycol.
  • Diethanolamine is added to a suspension of closantel in ethanol, benzyl alcohol, and propylene glycol. With stirring, the salt of closantel forms in situ, forming a solution. Moxidectin is then added, and stirred until solution is obtained. The formulation is then brought to volume with propylene glycol.
  • a solution of closantel in a mixed solvent system of acetonitrile and tetrahydrofuran is treated with an equimolar amount of monoisopropanolamine.
  • the reaction is stirred at 40°C, and then room temperature. Evapoaration of the solvents leads to the isolation of the monoisopropanolamine salt of closantel. After purification using the standard methods, the salt is characterized.
  • a solution of closantel in a mixed solvent system of acetonitrile and tetrahydrofuran is treated with an equimolar amount of diisopropanolamine.
  • the reaction is stirred at 40°C, and then room temperature. Evaporation of the solvents leads to the isolation of the diisopropanolamine salt of closantel. After purification using the standard methods, the salt is characterized.
  • additional excipient solvents can be used, such as N-methylpyrrolidone, 2-pyrrolidone or other pharmaceutically acceptable pyrrolidone solvents such as other alkyl or substituted alkyl pyrrolidones.
  • Ethanolamine is added to a suspension of closantel in benzyl alcohol, 2-pyrrolidone and polypropylene glycol 400. With stirring, the salt of formed in situ, forming a solution. Moxidectin is then added, and stirred until solution is obtained. The formulation is then brought to volume with PEG 400.
  • Solvents for the formation of acceptable pour on and/or injectable formulations of the alkanolamine salts of closanatel are not limited to the aforementioned examples. Solvents which are pharmaceutcally acceptable for dermal application can be used.
  • Examples include 2-pyrrolidone, N-methyl pyrrolidone, Polethylene glycol 200, Polyethylene glycol 400 and other PEG molecular weight cuts, other alkyl pyrrolidones such as lauryl pyrrolidone, octyl pyrrolidone, and hydroxyethyl pyrrolidone, gamma-hydroxylactone, benzyl alcohol, dimethyl isosorbide, gycerol formal, dimethylacetamide, aromatic petroleum solvents, PPG2 myristyl ether propionate, other alkyl ether alkyl esters, mixed capric/caprylic glyceryl triesters and other mixed esters of glycerol.
  • alkyl pyrrolidones such as lauryl pyrrolidone, octyl pyrrolidone, and hydroxyethyl pyrrolidone, gamma-hydroxylactone
  • benzyl alcohol dimethyl iso
  • test pour-on formulations are applied directly to the hair and skin in a narrow strip extending along the top of the back from the withers to the base of the tail.
  • Application is made to the healthy skin, avoiding any scabs, skin lesions or extraneous foreign matter.
  • Treatment is made using unarmed disposable syringes.
  • the correct dose volume is calculated based on each animal's body weight on the day of treatment.
  • composition for use in the invention demonstrates a significant increase in the blood levels of closantel alkanol amine salts.
  • TABLE I ⁇ g closantel/mL plasma Treatment Group Dose mg/kg Day 2 Day 3 Day 4 Day 7 Day 10 Day 14 Day 21 Day 28 A 30 5.47 5.98 6.35 7.3 9.35 10.5 8.70 8.30 A 30 4.32 5.07 5.64 6.84 5.93 5.94 4.56 2.97 A 30 8.39 10.39 11.39 12.55 13.95 15.11 10.21 8.98 Avg.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

There is provided an improved antiparasitic composition comprising an effective amount of an organic amine salt of closantel, a pharmacologically acceptable carrier, and an antiparasitically effective amount of a macrocyclic lactone.

Description

    BACKGROUND OF THE INVENTION
  • Parasites, such as helminths, are found in many animals, particularly grazing animals, and are responsible for significant economic losses throughout the world. Among the helminths most frequently encountered in grazing animals such as cattle, horses, goats and sheep are trematodes, i.e., flukes, for instance, Fasciola hepatica, and nematodes such as Haemonchus contortus. A valuable tool for the treatment of homeothermic animals suffering from such parasites is closantel (United States Patent 4,005,218 and Merck Index, 13th Edition).
  • Closantel is known to demonstrate little or no capacity for transdermal penetration at present, so the most effective means of administering closantel involves parenteral or oral administration. Commercially, Closantel is sold as its sodium salt, under Flukiver® for subcutaneous administration and Seponver® as an oral drench. Although the use of the sodium salt of closantel in a topical liquid composition is described in WO 97/13508 , there still remains a need for closantel compositions which exhibit improved transdermal penetration properties, as well as increased bioavailability. It is apparent that, not withstanding high safety margins, a lower but effective dosage is always preferred.
  • US-A-4 005 218 discloses salicylanilide derivatives, including closantel and amine addition salts thereof, which are parasiticides with activity against, inter alia, Fasciola hepatica or Haemonchus contortus. Examples of amine salts are the piperidine, piperazine, triethylamine, N-methylglucamine, methylamine, α-methylbenzylamine and ethanolamine salts. The compounds can be administered orally, parenterally or by external application by direct contact onto the skin.
  • Therefore, it is an object of this invention to provide improved antiparasitic compositions which, when administered to a homeothermic animal, increase the levels of closantel in the blood of said animal.
  • It is another object of this invention to provide enhanced protection of a homeothermic animal from parasitic infection.
  • It is a feature of this invention that the improved antiparasitic compositions are to be administered to a homeothermic animal by transdermal application, either alone, or in combination, with other antiparasitic compounds, as specified in claim 1.
    • SUMMARY OF THE INVENTION
  • The present invention provides the use of an antiparasitic composition having improved blood levels of closantel which comprises an antiparasitically effective amount of an alkanolamine salt of closantel, optionally an antiparasitically effective amount of a macrocyclic lactone, and a pharmacologically acceptable carrier, as specified in claim 1, in the manufacture of a medicament for the enhanced prevention, amelioration or control of a parasitic infection in a homeothermic animal by transdermal administration.
    • DETAILED DESCRIPTION OF THE INVENTION
  • Although closantel is known to be effective as a flukicide, its topical application has been limited due to its low capacity for transdermal penetration. Surprisingly, it has now been found that an antiparasitic composition, having an alkanolamine salt of closantel as an active component, significantly increases the bioavailability of closantel. While not wishing to be bound by a particular theory, it is believed that in its alkanolamine salt form, for example, as the ethanolamine salt, closantel is absorbed by passive diffusion in the liver. This achieves higher liver levels and, consequently, higher blood levels. Hence, there is potential for increased antiparasitic activity against, for example, Fasciola hepatica, Haemonchus contortus, Taenia pisiformis.
  • Advantageously, an antiparasitic composition for use in the invention containing an alkanolamine salt of closantel demonstrates improved transdermal penetration properties, thus allowing for administration in the form of a pour-on composition. Pour-on compositions are particularly suitable for treating parasites in grazing animals such as cattle, goats or sheep. The composition for use in the invention may also be suitable for administration by intramuscular or subcutaneous injection at a diversity of sites on an animal.
  • A further advantage of the use of the organic amine salt is that such can be more easily formulated with other anthelmintic agents, particularly those of the macrocyclic lactone type, which results in compositions that can be utilized to treat both nematodes and flukes (trematodes) in a single application.
  • Accordingly, the present invention provides the use of an improved antiparasitic composition which comprises an antiparasitically effective amount of an alkanolamine salt of closantel, and a pharmacologically acceptable carrier, and optionally a macrocyclic lactone, according to claim 1, for the manufacture of a medicament for the prevention, amelioration or control of a parasitic infection in a homeothermic animal by transdermal administration. Alkanolamine salts of closantel suitable for use in the invention include alkanolamine salts having 2-10 carbon atoms, and most preferred are the ethanolamine salts, i.e., closantel monoethanolamine or diethanolamine salts. Typically, such salts are prepared by contacting closantel with a solution of the alkanolamine. Organic amine salts are generally described, for instance, in United States Patent 4,005,218 .
  • Macrocyclic lactones for use in the invention are milbemycins and avermectins selected from moxidectin, abamectin, ivermectin, eprinomectin and doramectin, and preferably moxidectin. These compounds, and their anthelmintic activity, are described more particularly in U.S. Patent 4,916,154 (moxidectin), U.S. Patent 4,310,519 (abamectin), U.S. Patent 4,199,569 (ivermectin), U.S. Patent 4,427,663 (eprinomectin).
  • The pharmacologically acceptable carrier for use in the compositions of the present invention can be selected from typical solvents and excipients utilized for veterinary formulations. Preferably, the alkanolamine salt of closantel is dissolved in the carrier, although suspensions in either liquid or gel formulations are also effective. When a macrocyclic lactone is included as an optional ingredient, it may be present either in solution or in suspension.
  • Alcohols suitable for use in the composition for use in the invention include ethanol, benzyl alcohol, isopropanol, butanol, or a mixture thereof, with ethanol, benzyl alcohol or a mixture thereof being preferred.
  • Glycol derivatives suitable for use in the invention include propylene glycol, diethylene glycol monoethyl ether (transcutol), ethylene glycol, butylene glycol, polyethylene glycol, and preferably are propylene glycol, diethylene glycol monoethyl ether or a mixture thereof.
  • Antiparasitically effective amounts may vary according to the mode of application, the degree of infection, the target parasite species, the host homeothermic animal. In general, amounts of 5% w/v to 60% w/v of an alkanolamine salt of closantel, and optionally 0.1% w/v to 5.0% w/v of a macrocyclic lactone, are suitable for use in the invention.
  • The compositions for use in the invention may also include excipients such as surfactants, preferably oleic acid, thickening agents, salts, buffers, polyvinylpyrrolidone, or any conventional inert excipient commonly used in a pharmaceutical composition. The amount of said excipients may range from 0.1% w/v to 20% w/v.
  • Typical compositions for use in the invention may be prepared by admixing a glycol derivative with the alkanolamine salt of closantel and allowing said salt of closantel to solubilize to give a solution of the alkanolamine salt of closantel in the glycol derivative and treating this solution with an alcohol, which may optionally contain a macrocyclic lactone.
  • Advantageously, the compositions for use in the invention provide increased blood levels of closantel which are associated with the enhanced protection of a homeothermic animal against infection or infestation of parasites, particularly helminths.
  • Homeothermic animals suitable for treatment of the invention include grazing animals such as cattle, goats, sheep, llamas, deer, bison, etc.
  • Effective amounts may vary according to the general health of the animal, the degree of infection of infestation, the parasite species, the age of the animal, the organs infected or infested. In general, amounts of said composition sufficient to provide 5 mg/kg to 100 mg/kg, preferably 25 mg/kg to 50 mg/kg of closantel per body weight of the animal, and, optionally, 0.1 mg/kg to 2.0 mg/kg, preferably 0.1 mg/kg to 1.0 mg/kg of moxidectin per body weight of the animal are suitable.
  • For a clearer understanding of the invention, the following examples are set forth below. These examples are merely illustrative.
  • In the following examples, the term "qs" designates "quantity sufficient."
    • EXAMPLE 1
  • Preparation Of A Pour-On Formulation Containing An Alkanol Amine Salt Of Closantel
    Ingredients g/200 mL % w/v
    Closantel 60.00 30.00
    Diethylene glycol 60.0 30.00
    Monoethyl ether
    Ethanol amine 6.6 3.30
    Benzyl alcohol 10.0 5.00
    Oleic acid 60.0 30.00
    Moxidectin 1.04 0.52
    Ethanol, USP qs to 200 ml qs to 100
  • A stirred mixture of closantel in diethylene glycol monoethyl ether is treated with ethanolamine, and stirring is continued until solution is complete, thus forming the salt in situ. To this solution is then added a solution of moxidectin in benzyl alcohol, followed by the addition of oleic acid and ethanol. Stirring is continued until the mixture is homogeneous.
    • EXAMPLE 2 (Reference)
  • Preparation Of An Injectable Formulation Containing An Alkanol Amine Salt Of Closantel
    % w/v
    Ingredients A B
    Ethanolamine salt of closantel 12.9 16.0
    Glycerol formal -- 40.0
    Propylene glycol 45.0 --
    Benzyl alcohol 10.0 10.0
    Polyvinylpyrrolidone 7.0 --
    Deionized water 7.0 --
    Ethanol, USP 15.0 --
    Moxidectin (90%) 1.1 2.0
    Polyethylene glycol -- qs to 100
    Propylene glycol qs to 100 --
    • Preparation of Injectable Formula A
  • To a solution of the ethanol amine salt of closantel in propylene glycol is added a solution of moxidectin in benzyl alcohol, with stirring until homogenous, thus forming the salt in situ. To this is then added a solution of polyvinylpyrrolidone in deionized water, ethanol and additional propylene glycol. The resultant mixture is stirred until homogeneous.
    • Preparation of Injectable Formula B
  • To a solution of the ethanol amine salt of closantel in glycerol formal is added a solution of moxidectin in benzyl alcohol, with stirring until homogenous. To this is then added polyethylene glycol and the resultant mixture is stirred until homogeneous.
    • EXAMPLES 3-5 Preparation of Ethanol Amine Closantel Pour-On Formulations Having 10% w/v, 20% w/v and 30% w/v Closantel
  • Using essentially the same procedure described in Example 1, the pour-on formulations shown below are prepared.
    • EXAMPLE 3 - 10% w/v CLOSANTEL POUR-ON
  • Ingredient % w/v
    Closantel 11.0
    Diethylene glycol 30.0
    Monoethyl ether
    Ethanol amine 1.3
    Oleic acid 30.0
    10% solution of Moxidectin 5.0
    in benzyl alcohol
    Ethanol, USP qs to 100
    • EXAMPLE 4 - 20% W/V CLOSANTEL POUR-ON
  • Ingredient % w/v
    Closantel 22.0
    Diethylene glycol 30.0
    Monoethyl ether
    Ethanol amine 2.6
    Oleic acid 30.0
    10% solution of Moxidectin 5.0
    in benzyl alcohol
    Ethanol qs to 100
    • EXAMPLE 5 - 30% W/V CLOSANTEL POUR-ON
  • Ingredient % w/v
    Closantel 33.0
    Diethylene glycol 30.0
    Monoethyl ether
    Ethanolamine 3.0
    Oleic acid 19.0
    10% solution of Moxidectin 15.0
    in benzyl alcohol
    Ethanol qs to 100
    • EXAMPLE 6
  • Preparation Of A Pour-On Formulation Containing An Alkanol Amine Salt Of Closantel
    Ingredients g/200 mL % w/v
    Closantel 66.00 30.00
    Diethylene glycol 60.0 30.00
    Monoethyl ether
    Ethanolamine 6.6 3.30
    Oleic acid 60.0 30.00
    Ethanol, USP qs to 200 ml qs to 100
  • A stirred mixture of sodium closantel in diethylene glycol monoethyl ether is treated with ethanol amine, and stirring is continued until solution is complete, thus forming the salt in situ. To this solution is then added a solution of oleic acid and ethanol. Stirring is continued until the mixture is homogeneous.
    • EXAMPLE 7 (Reference)
  • Preparation Of An Injectable Formulation Containing An Alkanol Amine Salt Of Closantel
    % w/v
    Ingredients A B
    Ethanol amine salt of closantel 12.9 16.0
    Glycerol formal -- 40.0
    Propylene glycol 45.0 --
    Polyvinylpyrrolidone 7.0 --
    Deionized water 7.0 --
    Ethanol, USP 15.0 --
    Polyethylene glycol -- qs to 100
    Propylene glycol qs to 100 --
    • Preparation of Injectable Formula A
  • A solution of the ethanolamine salt of closantel in propylene glycol is stirred until homogenous, thus forming the salt in situ. To this is then added a solution of polyvinylpyrrolidone in deionized water, ethanol and additional propylene glycol. The resultant mixture is stirred until homogeneous.
    • Preparation of Injectable Formula B
  • To a solution of the ethanolamine salt of closantel in glycerol formal is added polyethylene glycol and the resultant mixture is stirred until homogeneous.
    • EXAMPLES 8-10 Preparation of Ethanolamine Closantel Pour-On Formulations Having 10% w/v, 20% w/v and 30% w/v Closantel
  • Using essentially the same procedure described in Example 6, the pour-on formulations shown below are prepared.
    • EXAMPLE 8 - 10% w/v Closantel Pour-on
  • Ingredient % w/v
    Closantel 11.0
    Diethylene glycol 30.0
    Monoethyl ether
    Ethanolamine 1.3
    Oleic acid 30.0
    Ethanol, USP qs to 100
    • EXAMPLE 9 - 20% w/v Closantel Pour-on
  • Ingredient % w/v
    Sodium closantel 22.0
    Diethylene glycol 30.0
    Monoethyl ether
    Ethanol amine 2.6
    Oleic acid 30.0
    Ethanol qs to 100
    • EXAMPLE 10 - 30% w/v Closantel Pour-on
  • Ingredient % w/v
    Closantel 33.0
    Diethylene glycol 30.0
    Monoethyl ether
    Ethanolamine 3.0
    Oleic acid 19.0
    Ethanol qs to 100
    • EXAMPLE 11 POUR ON FORMULATION CONTAINING THE AMINOMETHYLPROPANOL SALT OF CLOSANTEL AND MOXIDECTIN
  • Ingredient % w/v
    Closantel 30.0
    Aminomethylpropanol 2.2
    Diethylene glycol monoethyl ether 30.1
    Moxidectin 0.8
    Benzyl Alcohol 7.3
    Oleic Acid 30.0
  • Using the preparation scheme from Example 6, substitute aminomethylpropanol for ethanolamine.
    • EXAMPLE 12 (Reference) INJECTABLE FORMULATION CONTAINING N-METHYLGLUCAMINE SALT OF CLOSANTEL AND MOXIDECTIN
  • Ingredient % w/v
    N-methylglucamine Salt of Closantel 18.75
    Moxidectin 0.67
    Benzyl Alcohol 10.00
    Ethanol 15.00
    Propylene Glycol q.s.
  • N-methylglucamine is added to a suspension of closantel in ethanol, benzyl alcohol, and propylene glycol. With stirring, the salt of closantel forms in situ, forming a solution. Moxidectin is then added, and stirred until solution is obtained. The formulation is then brought to volume with propylene glycol.
    • EXAMPLE 13 (Reference) INJECTABLE FORMULATION CONTAINING DIETHANOLAMINE SALT OF CLOSANTEL AND MOXIDECTIN
  • Ingredient % w/v
    Diethanolamine Salt of Closantel 18.75
    Moxidectin 0.67
    Benzyl Alcohol 10.00
    Ethanol 15.00
    Propylene Glycol q.s.
  • Diethanolamine is added to a suspension of closantel in ethanol, benzyl alcohol, and propylene glycol. With stirring, the salt of closantel forms in situ, forming a solution. Moxidectin is then added, and stirred until solution is obtained. The formulation is then brought to volume with propylene glycol.
  • Additional to the in situ formation of organic amine salts of closantel, these salts can be prepared, isolated and characterized by those skilled in the art
    • EXAMPLE 14
  • A solution of closantel in a mixed solvent system of acetonitrile and tetrahydrofuran is treated with an equimolar amount of monoisopropanolamine. The reaction is stirred at 40°C, and then room temperature. Evapoaration of the solvents leads to the isolation of the monoisopropanolamine salt of closantel. After purification using the standard methods, the salt is characterized.
    • EXAMPLE 15
  • A solution of closantel in a mixed solvent system of acetonitrile and tetrahydrofuran is treated with an equimolar amount of diisopropanolamine. The reaction is stirred at 40°C, and then room temperature. Evaporation of the solvents leads to the isolation of the diisopropanolamine salt of closantel. After purification using the standard methods, the salt is characterized.
  • Other additional excipient solvents can be used, such as N-methylpyrrolidone, 2-pyrrolidone or other pharmaceutically acceptable pyrrolidone solvents such as other alkyl or substituted alkyl pyrrolidones.
    • EXAMPLE 16 (Reference) INJECTABLE FORMULATION CONTAINING ETHANOLAMINE SALT OF CLOSANTEL AND MOXIDECTIN
  • Ingredient % w/v
    Monoethanolamine Salt of Closantel 12.6
    Moxidectin 1.0
    Benzyl Alcohol 10.0
    2-pyrrolidone 38.3
    Polyethylene Glycol 400 q.s.
  • Ethanolamine is added to a suspension of closantel in benzyl alcohol, 2-pyrrolidone and polypropylene glycol 400. With stirring, the salt of formed in situ, forming a solution. Moxidectin is then added, and stirred until solution is obtained. The formulation is then brought to volume with PEG 400.
  • Solvents for the formation of acceptable pour on and/or injectable formulations of the alkanolamine salts of closanatel are not limited to the aforementioned examples. Solvents which are pharmaceutcally acceptable for dermal application can be used. Examples include 2-pyrrolidone, N-methyl pyrrolidone, Polethylene glycol 200, Polyethylene glycol 400 and other PEG molecular weight cuts, other alkyl pyrrolidones such as lauryl pyrrolidone, octyl pyrrolidone, and hydroxyethyl pyrrolidone, gamma-hydroxylactone, benzyl alcohol, dimethyl isosorbide, gycerol formal, dimethylacetamide, aromatic petroleum solvents, PPG2 myristyl ether propionate, other alkyl ether alkyl esters, mixed capric/caprylic glyceryl triesters and other mixed esters of glycerol.
    • EXAMPLE 17 POUR ON FORMULATION CONTAINING THE AMI NOMETHYLPROPANOL SALT OF CLOSANTEL AND MOXIDECCTIN
  • Ingredient % w/v
    Closantel 30.0
    Aminomethylpropanol 2.2
    Diethylene glycol 30.1
    monoethyl ether
    Moxidectin 0.8
    Benzyl Alcohol 7.3
    Oleic Acid 30.0
  • Using the preparation scheme from Example 6, substitute aminomethylpropanol for ethanolamine.
    • EXAMPLE 18
  • Comparative Evaluation Of The Blood Levels Of Closantel Following The Application Of A Pour-On Formulation Containing The Sodium Salt Of Closantel Vs The Ethanolamine Salt Of Closantel
  • In this evaluation weaned Holstein steer calves are treated with fenbendazole to remove any nematode infections present. The calves are then divided into test groups and maintained in accordance with the guidelines in the current Guide for the Care and Use of Agricultural Animals in Agricultural Research and Teaching. Animals are blocked into three blocks based on body weight and each animal within a block is randomly assigned to treatment group A or B. On day 0 of the study, all animals are weighed and each animal in each group is treated with a pour-on formulation as indicated in the experimental design. The pour-on formulations are administered at a rate of 0.1 mL formulation per kg of body weight (rounded to the nearest full mL). The test pour-on formulations are applied directly to the hair and skin in a narrow strip extending along the top of the back from the withers to the base of the tail. Application is made to the healthy skin, avoiding any scabs, skin lesions or extraneous foreign matter. Treatment is made using unarmed disposable syringes. The correct dose volume is calculated based on each animal's body weight on the day of treatment.
  • On Day 0, prior to treatment, and on Day 1, 2, 3, 4, 7, 10, 14, 21 and 28 post treatment, blood samples are collected from each experimental animal. The blood samples are centrifuged soon after collection at about 1000 Xg for approximately 25 minutes. Plasma is removed and equal amounts are stored at -20°C. During handling and storage, care is taken not to expose the plasma samples to direct sunlight. Duplicate plasma samples from each animal are analyzed for closantel. The results are shown in Table 1.
    • TREATMENT A - SODIUM CLOSANTEL POUR-ON
  • Ingredient g/200 mL % w/v
    sodium closantel 66.0 33.0
    propylene glycol 60.0 30.0
    diethylene glycol 60.0 30.0
    monoethyl ether
    benzyl alcohol 10.0 5.0
    moxidectin 1.0 0.5
    ethanol qs to 200 mL qs to 100
  • Using essentially the same procedure described in Example 1 and employing the ingredients listed hereinabove, a sodium closantel pour-on was prepared and used in this evaluation as treatment A.
    • TREATMENT B - Ethanolamine Closantel Pour-on
  • The ethanolamine closantel pour-on formulation described in Example 1 was used in this evaluation as treatment B.
    • SUMMARY OF RESULTS
  • As can be seen from the data shown on Table I the composition for use in the invention demonstrates a significant increase in the blood levels of closantel alkanol amine salts. TABLE I
    µg closantel/mL plasma
    Treatment Group Dose mg/kg Day 2 Day 3 Day 4 Day 7 Day 10 Day 14 Day 21 Day 28
    A 30 5.47 5.98 6.35 7.3 9.35 10.5 8.70 8.30
    A 30 4.32 5.07 5.64 6.84 5.93 5.94 4.56 2.97
    A 30 8.39 10.39 11.39 12.55 13.95 15.11 10.21 8.98
    Avg. 6.06 7.15 7.8 8.90 9.74 10.52 7.80 6.80
    B 30 7.22 10.61 11.73 14.66 15.68 15.51 16.77 14.23
    B 30 3.9 6.21 7.66 9.97 11.65 14.44 13.58 14.38
    B 30 6.7 12.97 17.46 18.89 20.52 28.53 25.09 19.08
    Avg. 5.94 9.93 12.28 14.51 15.95 19.49 18.48 15.90

Claims (8)

  1. The use of an alkanolamine salt of closantel, and a pharmacologically acceptable carrier, and optionally a macrocyclic lactone selected from the group consisting of moxidectin, abamectin, doramectin, eprinomectin and ivermectin, in the manufacture of a medicament for the prevention, amelioration or control of a parasitic infection in a homeothermic animal by transdermal administration.
  2. The use according to claim 1 wherein said macrocyclic lactone is moxidectin.
  3. The use according to claim 1 or 2 wherein the alkanolamine salt is an ethanolamine salt.
  4. The use according to any one of claims 1 to 3 wherein the parasitic infection is caused by the parasite selected from the group consisting essentially of Fasciola hepatica and Haemonchus contortus.
  5. The use according to any one of claims 1 to 4 wherein the homeothermic animal is selected from the group consisting of cattle and sheep.
  6. The use according to any one of claims 1 to 5 wherein said medicament is adapted for administration as a pour-on.
  7. The use according to any one of claims 1 to 6 wherein said pharmacologically acceptable carrier is selected from the group consisting of benzyl alcohol; ethanol; or a mixture thereof, and propylene glycol; diethylene glycol monoethyl ether; or a mixture thereof.
  8. The use according to any one of claims 1 to 7 wherein said medicament is adapted to provide 2.5 mg/kg to 50 mg/kg of the ethanolamine salt of closantel and 0.1 mg/kg to 1.0 mg/kg of moxidectin.
EP05712747A 2004-02-02 2005-01-28 Antiparasitic composition containing an organic amine salt of closantel Active EP1713466B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP09003554A EP2065042A3 (en) 2004-02-02 2005-01-28 Antiparasitic composition containing an organic amine salt of closantel

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54116204P 2004-02-02 2004-02-02
PCT/US2005/003413 WO2005074912A2 (en) 2004-02-02 2005-01-28 Antiparasitic composition containing an organic amine salt of closantel

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP09003554A Division EP2065042A3 (en) 2004-02-02 2005-01-28 Antiparasitic composition containing an organic amine salt of closantel

Publications (2)

Publication Number Publication Date
EP1713466A2 EP1713466A2 (en) 2006-10-25
EP1713466B1 true EP1713466B1 (en) 2009-03-18

Family

ID=34837467

Family Applications (2)

Application Number Title Priority Date Filing Date
EP09003554A Withdrawn EP2065042A3 (en) 2004-02-02 2005-01-28 Antiparasitic composition containing an organic amine salt of closantel
EP05712747A Active EP1713466B1 (en) 2004-02-02 2005-01-28 Antiparasitic composition containing an organic amine salt of closantel

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP09003554A Withdrawn EP2065042A3 (en) 2004-02-02 2005-01-28 Antiparasitic composition containing an organic amine salt of closantel

Country Status (11)

Country Link
US (1) US7666444B2 (en)
EP (2) EP2065042A3 (en)
AT (1) ATE425751T1 (en)
AU (1) AU2005210660A1 (en)
BR (1) BRPI0507333A (en)
CA (1) CA2553039A1 (en)
DE (1) DE602005013360D1 (en)
ES (1) ES2323137T3 (en)
MX (1) MXPA06008751A (en)
NZ (1) NZ548689A (en)
WO (1) WO2005074912A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1824474A1 (en) * 2004-12-10 2007-08-29 Bayer HealthCare AG Anthelmintic composition
AU2013201461B2 (en) * 2007-11-26 2015-10-29 Boehringer Ingelheim Animal Health USA Inc. Solvent systems for pour-on formulations for combating parasites
WO2009070687A1 (en) * 2007-11-26 2009-06-04 Merial Limited Solvent systems for pour-on formulations for combating parasites
WO2010106325A2 (en) 2009-03-18 2010-09-23 Omnipharm Limited Parasiticidal formulation
GB201021836D0 (en) * 2010-12-21 2011-02-02 Norbrook Lab Ltd Topical Composition
MX2017003251A (en) 2014-09-12 2017-12-20 Antibiotx Aps Antibacterial use of halogenated salicylanilides.
GB201509326D0 (en) 2015-05-29 2015-07-15 Antibio Tx Aps Novel use
UY37137A (en) 2016-02-24 2017-09-29 Merial Inc ANTIPARASITARY COMPOUNDS OF ISOXAZOLINE, INJECTABLE FORMULATIONS OF PROLONGED ACTION THAT INCLUDE THEM, METHODS AND USES OF THE SAME
GB201604484D0 (en) * 2016-03-16 2016-04-27 Antibiotx Aps And Københavns Uni University Of Copenhagen Topical antibacterial compositions
US11419834B2 (en) 2019-02-25 2022-08-23 Rhode Island Hospital Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide
CN110279657B (en) * 2019-07-29 2021-07-27 河南官渡生物工程有限公司 Closantel sodium injection and preparation method thereof
EP3815677B1 (en) 2019-10-30 2023-08-30 KRKA, d.d., Novo mesto Stable veterinary composition comprising moxidectin and imidacloprid

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4005218A (en) * 1975-03-18 1977-01-25 Janssen Pharmaceutica N.V. Antiparasitic salicylanilide derivatives
SE434277B (en) 1976-04-19 1984-07-16 Merck & Co Inc SET TO MAKE NEW ANTIHELMINTICALLY EFFECTIVE ASSOCIATIONS BY CULTIVATING STREPTOMYCS AVERMITILIS
US4199569A (en) 1977-10-03 1980-04-22 Merck & Co., Inc. Selective hydrogenation products of C-076 compounds and derivatives thereof
US4427663A (en) * 1982-03-16 1984-01-24 Merck & Co., Inc. 4"-Keto-and 4"-amino-4"-deoxy avermectin compounds and substituted amino derivatives thereof
US4916154A (en) 1986-09-12 1990-04-10 American Cyanamid Company 23-Imino derivatives of LL-F28249 compounds
US5169846A (en) * 1989-10-12 1992-12-08 Crooks Michael J Non-aqueous micellar solutions of anthelmintic benzimidazoles, closantel, or phenothiazine, and insect growth regulators
NZ267366A (en) 1993-06-15 1996-12-20 Univ Australian Controlling fasciola and other helminths using a synergistic composition of at least two anthelmintic active drugs each being selected from a different class of drug
NZ248486A (en) 1993-08-24 1996-07-26 Ashmont Holdings Limited Subst Stable anthelmintic formulation containing closantel and one or more avermectins or milbemycins in a glycol based solvent
FR2739778B1 (en) 1995-10-13 1997-12-12 Virbac Lab TOPICAL FORMULATION FOR TREATING LIVER DISEASE DISEASE IN ANIMALS
GB9825402D0 (en) * 1998-11-19 1999-01-13 Pfizer Ltd Antiparasitic formulations
AUPQ441699A0 (en) * 1999-12-02 2000-01-06 Eli Lilly And Company Pour-on formulations
US6340672B1 (en) * 2000-02-16 2002-01-22 Phoenix Scientific, Inc. Parasiticidal formulation and a method of making this formulation
AUPQ875700A0 (en) 2000-07-13 2000-08-03 Reflex Research Limited Combination compositions
CN1375287A (en) 2001-03-16 2002-10-23 王玉万 Veterinary mixed suspension injection containing chlorocyaniosaliamine or its sodium salt
AU2003215011A1 (en) 2002-02-08 2003-09-02 Mcneil-Ppc, Inc. Topical ivermectin composition
GB2386066A (en) 2002-02-28 2003-09-10 Norbrook Lab Ltd Long-acting parasiticidal composition with improved bioavailability comprising a salicylanilide, a further anti-parasitic compound & a polymeric species
GB2386067A (en) 2002-02-28 2003-09-10 Norbrook Lab Ltd Long-acting parasiticidal composition with improved bioavailability comprising an avermectin or milbemycin, plus a salicylanilide & a polymeric species
FR2839614B1 (en) 2002-05-14 2004-08-13 Virbac Sa NEW OIL PEST ORAL OIL COMPOSITIONS
US6653288B1 (en) * 2002-09-30 2003-11-25 Virbac S.A. Injectable anthelmintic compositions and methods for using same
AU2002952597A0 (en) 2002-11-11 2002-11-28 Schering-Plough Pty. Limited Topical parasiticide formulations and methods of treatment
AU2003284802A1 (en) 2002-11-27 2004-06-18 Eco Animal Health Ltd An injection of animal remedy including closantel or closantel sodium
MXPA05010659A (en) 2003-04-04 2005-12-12 Merial Ltd Topical anthelmintic veterinary formulations.

Also Published As

Publication number Publication date
EP2065042A2 (en) 2009-06-03
EP1713466A2 (en) 2006-10-25
CA2553039A1 (en) 2005-08-18
DE602005013360D1 (en) 2009-04-30
US7666444B2 (en) 2010-02-23
WO2005074912A2 (en) 2005-08-18
BRPI0507333A (en) 2007-07-03
WO2005074912A3 (en) 2006-04-20
ES2323137T3 (en) 2009-07-07
US20050197302A1 (en) 2005-09-08
AU2005210660A1 (en) 2005-08-18
NZ548689A (en) 2010-06-25
EP2065042A3 (en) 2009-07-22
ATE425751T1 (en) 2009-04-15
MXPA06008751A (en) 2007-01-19

Similar Documents

Publication Publication Date Title
EP1713466B1 (en) Antiparasitic composition containing an organic amine salt of closantel
EP1505975B1 (en) Compositions and method for treating infection in cattle and swine
EP1455782B1 (en) High-concentration stable meloxicam solutions for needle-less injection
EP1610613B1 (en) Topical anthelmintic veterinary formulations
EP0546018B1 (en) Pharmaceutical composition of florfenicol
US8034845B2 (en) Compositions and method for treating infection in cattle and swine
EP1941880B1 (en) Lotion preparation containing pyridonecarboxylic acid derivative
JPS60169415A (en) Non-aqueous ivermectin prescription having improved antivermifugal activity
EP1613354B1 (en) Use of cyclic acetals/ cetals for improved penetration of active substances into cells and organs
US20060287353A1 (en) Method for preventing or treating ischemia-or hemorrhage-induced brain damage using a macrolide compound
US8217062B2 (en) Topical composition comprising a dihydropyridine calcium antagonist
EP0238207B1 (en) Bactericidal mixtures
SK5682000A3 (en) Compositions containing thiamphenicol and diclofenac
KR101625926B1 (en) Method and improved pharmceutical composition for enhancing transderaml delivery of pde-5 inhibitor
EP1875913A1 (en) Compositions and method for treating infection in cattle and swine
AU2006233264A1 (en) Compositions and method for treating infection in cattle and swine

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060629

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR LV MK YU

17Q First examination report despatched

Effective date: 20061123

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR LV MK YU

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 602005013360

Country of ref document: DE

Date of ref document: 20090430

Kind code of ref document: P

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2323137

Country of ref document: ES

Kind code of ref document: T3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090318

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090318

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090318

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090618

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090318

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090318

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090318

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090826

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090318

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090718

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090318

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090318

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090618

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090318

26N No opposition filed

Effective date: 20091221

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20100126

Year of fee payment: 6

Ref country code: GB

Payment date: 20091211

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20100125

Year of fee payment: 6

Ref country code: IT

Payment date: 20100114

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20100201

Year of fee payment: 6

Ref country code: DE

Payment date: 20100129

Year of fee payment: 6

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100131

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20100118

Year of fee payment: 6

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090619

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100131

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100131

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100128

BERE Be: lapsed

Owner name: WYETH

Effective date: 20110131

REG Reference to a national code

Ref country code: NL

Ref legal event code: V1

Effective date: 20110801

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20110128

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20110930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110131

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110131

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110128

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602005013360

Country of ref document: DE

Effective date: 20110802

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110128

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110801

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20120220

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110129

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090318

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090919

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100128

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090318

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110802